Influence of antithymocyte globulin dose on outcome in cytomegalovirus-seropositive recipients of partially T cell-depleted stem cell grafts from matched-unrelated donors

British Journal of Haematology

Volumn 121, Issue 3, 2003, Pages 473-476

  Meijer, Ellen ^a   Dekker, Adriaan W ^a   Verdonck, Leo F ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

ATG; CMV; MUD; SCT; Survival

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FOSCARNET; GANCICLOVIR; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; THYMOCYTE ANTIBODY; VIRUS ANTIGEN; VIRUS DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; CYTOMEGALOVIRUS INFECTION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS REACTIVATION;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; LEUKEMIA; LYMPHOCYTE COUNT; MIDDLE AGED; REGRESSION ANALYSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 0037677921     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04294.x     Document Type: Article

References (12)

1. Craddock, C., Szydlo, R.M., Dazzi, F., Olavarria, E., Cwynarski, K., Yong, A., Brookes, P., de la Fuente, J., Kanfer, E., Apperley, J. & Goldman, J.M. (2001) Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. British Journal of Haematolooy, 112, 228-236.
2. Griscelli, F., Barrois, M., Chauvin, S., Lastere, S., Bellet, D. & Bourhis, J.H. (2001) Quantification of human cytomegalovirus DNA in bone marrow transplant recipients by real-time PCR. Journal of Clinical Microbioloogy, 39, 4362-4369.
3. Humar, A., Wood, S., Lipton, J., Messner, H., Meharchand, J., McGeer, A., MacDonald, K. & Mazzulli, T. (1998) Effect of cytomegalovirus infection on 1-year mortality rates among recipients of allogeneic bone marrow transplants. Clinical Infectious Diseases, 26, 606-610.
4. Kröger, N., Zabelina, T., Krüger, W., Renges, H., Stute, N., Schrum, J., Kabisch, H., Schafhausen, P., Jaburg, N., Loliger, C., Schafer, P., Hinke, A. & Zander, A.R. (2001) Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with antithymocyte globulin. British Journal of Haematolooy, 113, 1060-1071.
5. Machida, U., Kami, M., Fukui, T., Kazuyama, Y., Kinoshita, M., Tanaka, Y., Kanda, Y., Ogawa, S., Honda, H. & Hirai, H. (2000) Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation. Journal of Clinical Microbiology, 38, 2536-2542.
6. Meijer, E., Dekker, A.W., Rozenberg-Arska, M., Weersink, A.J.L. & Verdonck, L.F. (2002) Influence of cytomegalovirus-seropositivity on outcome after T cell depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. Clinical Infectious Diseases, 35, 703-712.
7. Meyers, J.D., Flournoy, N. & Thomas, E.D. (1986) Risk factors for cytomegalovirus infection after human marrow transplantation. Journal of Infectious Diseases, 153, 478-488.
8. Moutaftsi, M., Mehl, A.M., Borysiewicz, L.K. & Tabi, Z. (2002) Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood, 99, 2913-2921.
9. Nichols, W.G., Corey, L., Gooley, T., Davis, C. & Boeckh, M. (2002) High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. Journal of Infectious Diseases, 185, 273-282.
10. Peggs, K.S., Preiser, W., Kottaridis, P.D., McKeag, N., Brink, N.S., Tedder, R.S., Goldstone, A.H., Linch, D.C. & Mackinnon, S. (2000) Extended routine polymerase chain reaction surveillance and preemptive antiviral therapy for cytomegalovirus after allogeneic transplantation. British Journal of Haematology, 111, 782-790.
11. Yakushiji, K., Gondo, H., Kamezaki, K., Shigematsu, K., Hayashi, S., Kuroiwa, M., Taniguchi, S., Ohno, Y., Takase, K., Numata, A., Aoki, K., Kato, K., Nagafuji, K. & Harada, M. (2002) Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. Bone Marrow Transplantation, 29, 599-606.
12. Zaia, J.A. (1999) Cytomegalovirus infections. In: Hematopoietic Cell Transplantation (ed. by E.D. Thomas, K.G. Blume & S.J. Forman), pp. 560-583. Blackwell Science. Massachusetts.